argenx SE (NASDAQ:ARGX) Q4 2022 Earnings Call Transcript

And of course, Keith mentioned about the European launches and those investments in those countries are stage gate. We don’t put commercial colleagues in the market until such time, but we do have pricing and reimbursement in place. So the point is that, the SG&A number will increase quarter by quarter throughout 2023.

Tim Van Hauwermeiren: Thank you, Karl. And I’m very happy with the pemphigus question. Pemphigus is a significant unmet medical needs, there is hardly any option — treatment option out there for these patients. And the trial actually has been going very well. This is a global a Phase 3 registration trial on the back of very strong Phase 2 data. And I would say that the in autoimmune listing disease is participating in this trial. The trial enrolled extremely well. And from an endpoint’s point of view, the primary endpoint is complete remission on minimum dose of corticosteroids. So these patients really need stop information of new lesions, the closing of the existing lesions and then the tapering of steroids as fast as possible.

So minimum corticosteroid dose is the primary endpoint. In the second — in the second release, we will be looking at CR off therapy. We will be looking at quality of life and safety and the cumulative use of corticosteroids. These are the key secondary endpoints. So this is a data point to be expected for the second half of this year. Thank you for the question.

Operator: And there are no further questions at this time. This does conclude today’s conference call. Thank you for your participation. You may now disconnect.